Abbott BinaxNOW, Scaling COVID Testing

The Challenge

Abbott shipped BinaxNOW in August 2020. Demand instantly exceeded production forecasts by orders of magnitude. The platform managing distribution and result capture was still in pilot mode. Built for thousands of tests, not 50 million. Manufacturing, supply chain, regulatory compliance and eCommerce logistics all needed to synchronize but no one was orchestrating across them. The platform had no product strategy for population scale. Testing bottlenecks multiplied because the coordination layer didn’t exist.

I took over Abbott’s BinaxNOW population management platform mid-pilot.

Key Decisions

• Make next-day delivery the first release gate

  Stakeholders wanted every feature at once. I sequenced the rebuild around distribution logistics and held NAVICA enhancements and advanced analytics until the fulfillment pipeline was stable.

• Staff the six workstreams before writing the spec

  Failures spanned manufacturing handoffs, regulatory reviews and app workflows. I recruited across those workstreams before asking engineering to start a technical rebuild.

• Build compliance checks into production handoffs

  With regulatory and quality teams, I added checkpoints at manufacturing handoff, fulfillment and digital result capture. The checks added work up front and stopped repeated review delays later in the pipeline.

• Protect verification accuracy in NAVICA

  There was pressure to ship result capture quickly. I prioritized records that travel, employers and schools could trust over broader feature coverage; institutions would not use results they could not verify.

What I Delivered

• Population management platform

  Rebuilt the pilot platform to support mass-market test distribution, with workflows across manufacturing, logistics and digital result capture. Throughput and compliance moved forward together.

• Distribution program

  Coordinated eCommerce, fulfillment and supply-chain partners to deliver tests nationwide the next day. Stabilizing distribution first kept the program on schedule.

• NAVICA app integration

  Delivered result capture and verification for Abbott’s digital health app. Millions of Americans used these records for travel, work and school access.

Outcomes

The team reached 50 million tests per month about six weeks after the platform rebuild began. Distribution stabilized first, NAVICA verification shipped and the compliance pipeline handled surge volume without a regulatory incident.

Scaled throughput to 50M tests/month. By October 2020, the platform and distribution program handled 50 million tests per month. Volume rose to 30–90 million tests a month in the first half of 2021, sustaining supply through the winter surge and vaccine rollout.

Employers, schools and interstate travelers accepted NAVICA records when no trusted rapid-test verification standard existed. Abbott’s share of the U.S. rapid-test market peaked at roughly 65%.